Sensus Healthcare, Inc. (SRTS) AI Stock Analysis

Sensus Healthcare, Inc. is a medical device company that manufactures and distributes radiation therapy devices globally. The company focuses on superficial radiation therapy (SRT) utilizing low-energy X-rays across its portfolio. Its flagship system, the SRT-100, provides a non-surgical alternative for non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as skin conditions like keloids. Additional systems include the SRT-100 Vision, which features high-frequency ultrasound imaging and volumetric tumor analysis, and the SRT-100 Plus. Sensus also offers its Sentinel service program and provides in-office laser rental options to healthcare providers.

Revenue expanded from $27.0M in FY2021 to $44.5M in FY2022 before declining 45.2% to $24.4M in FY2023. While FY2024 revenue rebounded 71.3% to $41.8M, FY2025 revenue fell 34.3% to $27.5M. Profitability has fluctuated substantially: gross margin slipped from 66.5% in FY2022 to 43.2% in FY2025, and operating margin dropped to -37.5%. Consequently, net income shifted from $24.2M in FY2022 to a net loss of -$7.7M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $17.5M with an operating margin of -138.9%, as quarterly revenue fell 68.7% year-over-year.

As of June 30, 2026, Sensus Healthcare held $15.2M in cash and short-term investments against total debt of $343,000, yielding net cash of $14.8M. The company maintains liquidity with a current ratio of 8.71 and a debt-to-equity ratio of 0.01 against shareholders' equity of $36.9M. In FY2025, operating cash flow turned positive to $528,000 and free cash flow reached $332,000. Capital allocation in FY2025 included capital expenditures of $196,000 and share buybacks of $300,000.

At a market cap of $45.6M and enterprise value of $35.0M, SRTS trades at a price-to-sales multiple of 2.6x, compared to the median of 4.1x for its US-listed Healthcare peers. Its forward P/E is 21.4x, above the peer group median of 17.3x, while its EV-to-EBITDA stands at 8.7x compared to the peer median of 12.0x. Over the past year, the stock declined 16.3%, trailing the S&P 500 (SPY) gain of 16.8%. Over five years, the stock decreased 30.6% compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 3 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $5.38, representing 94.0% upside compared to the last close of $2.77 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.76 and revenue of $19.1M. Over the last four quarters, the company beat EPS estimates 1 time. Sensus Healthcare's next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of Sensus Healthcare, Inc. (SRTS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SRTS income statement, SRTS balance sheet, SRTS key metrics, SRTS analyst forecast, SRTS chart. See the SRTS stock overview for the latest quote and news.